(Q34393008)

English

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gram-negative bacteria

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

Sheryl A. Zelenitsky

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Philippe Lagacé-Wiens

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

George G Zhanel

1

object named as

George G Zhanel

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

James A. Karlowsky

13

object named as

James A Karlowsky

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Phillip Chung

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Heather Adam

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Andrew Denisuik

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Frank Schweizer

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ethan Rubinstein

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Alfred S Gin

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Andrew Walkty

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Daryl J Hoban

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Joseph P Lynch

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 January 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

74

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

31-51

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24352909%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

https://scigraph.springernature.com/pub.10.1007/s40265-013-0168-2

0 references

Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Progress and challenges in implementing the research on ESKAPE pathogens

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pseudomonas aeruginosa: all roads lead to resistance

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Three decades of beta-lactamase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Class A beta-lactamases--enzyme-inhibitor interactions and resistance

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Designing new β-lactams: implications from their targets, resistance factors and synthesizing enzymes

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Penicillin-binding proteins and beta-lactam resistance

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0168-2

21 January 2018

Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/24352909

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34393008&oldid=1940506162"